Julien Seneschal
Overview
Explore the profile of Julien Seneschal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
1792
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chovatiya R, Ribero S, Wollenberg A, Park C, Silvestre J, Hong H, et al.
Am J Clin Dermatol
. 2025 Mar;
PMID: 40085349
Background And Objective: There is a need for long-term atopic dermatitis (AD) treatments that can effectively improve AD involvement of the head and neck (H&N) region (referred to as H&N...
2.
Ly S, Beylot-Barry M, Seneschal J
J Eur Acad Dermatol Venereol
. 2025 Mar;
PMID: 40028665
No abstract available.
3.
Gupta A, Bamimore M, Seneschal J, Piguet V, Talukder M
J Cosmet Dermatol
. 2025 Feb;
24(3):e70078.
PMID: 40013382
Background: Vitiligo, a stigmatizing condition characterized by patchy depigmented skin, has an estimated global prevalence of 0.36%. This condition is a risk factor for anxiety, depression, and even suicidal ideation....
4.
Ezzedine K, Seneschal J, Corgibet F, Halioua B, Sampogna F, Merhand S, et al.
Acta Derm Venereol
. 2025 Feb;
105:adv42734.
PMID: 39964215
No abstract available.
5.
Seneschal J, Guyon M, Merhi R, Mazereeuw-Hautier J, Andreu N, Cazenave S, et al.
JAMA Dermatol
. 2025 Jan;
PMID: 39841460
Importance: Vitiligo is a chronic autoimmune disorder leading to skin depigmentation and reduced quality of life (QOL). Patients with extensive and very active disease are the most difficult to treat....
6.
Beyrouti A, Deuze J, Fontas E, Foureau A, Barbarot S, Aubert H, et al.
J Allergy Clin Immunol Pract
. 2024 Dec;
13(2):353-360.
PMID: 39672377
Background: Patients with atopic dermatitis (AD) may discontinue dupilumab owing to dupilumab-induced ocular adverse events (DOAEs) or dupilumab-induced facial redness (DFR). Objective: To evaluate DOAE and DFR outcomes after switching...
7.
Fargeas M, Fauvernier M, Tauber M, Seneschal J, Verdu V, Bourrel Bouttaz M, et al.
Acta Derm Venereol
. 2024 Dec;
104:adv41184.
PMID: 39670437
In the era of biological treatments and small molecules, this study assessed therapeutic patient education (TPE) in managing adult atopic dermatitis (AD), focusing on disease severity, quality of life, and...
8.
Fauthoux T, Brisou D, Lazaro E, Seneschal J, Constans J, Skopinski S, et al.
RMD Open
. 2024 Oct;
10(4).
PMID: 39424406
Introduction: Systemic sclerosis (SSc) is a serious life-threatening tissue disease. A significant aspect of its mortality arises from comorbid conditions. Our study aimed at mapping out the prevalence of these...
9.
Misery L, Seneschal J, Corgibet F, Halioua B, Sampogna F, Merhand S, et al.
Clin Exp Dermatol
. 2024 Sep;
50(2):422-423.
PMID: 39229930
No abstract available.
10.
Holzgruber J, Martins C, Kulcsar Z, Duplaine A, Rasbach E, Migayron L, et al.
Nat Commun
. 2024 Aug;
15(1):7165.
PMID: 39187481
Programmed cell death 1 (PD-1) is a premier cancer drug target for immune checkpoint blockade (ICB). Because PD-1 receptor inhibition activates tumor-specific T-cell immunity, research has predominantly focused on T-cell-PD-1...